Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
03.10. | Processa Pharmaceuticals behält "Kaufen"-Empfehlung von H.C. Wainwright | 1 | Investing.com Deutsch | ||
03.10. | Processa Pharmaceuticals maintains Buy rating from H.C. Wainwright | 2 | Investing.com | ||
03.10. | Aktie von Processa Pharmaceuticals erreicht 52-Wochen-Tief bei 1,26 US-Dollar | 1 | Investing.com Deutsch | ||
02.10. | Processa Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
02.10. | Processa stock rallies 35% post-market on Phase 2 study update | 1 | Seeking Alpha | ||
02.10. | Processa Pharmaceuticals, Inc.: Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer | 74 | GlobeNewswire (Europe) | Phase 2 trial is an adaptive designed randomized study comparing NGC-Cap to monotherapy capecitabineResults from this Phase 2 trial will evaluate NGC-Cap's safety-efficacy profile and help to define... ► Artikel lesen | |
06.09. | Processa Pharmaceuticals stock hits 52-week low at $1.3 | 1 | Investing.com | ||
03.09. | Processa Pharmaceuticals, Inc.: Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September | 1 | GlobeNewswire (USA) | ||
28.08. | Processa Pharmaceuticals reports GAAP EPS of -$1.01 | 1 | Seeking Alpha | ||
28.08. | Processa Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
20.08. | Processa Pharmaceuticals holds a target on positive study data | 1 | Investing.com | ||
19.08. | Processa Pharmaceuticals target cut by H.C. Wainwright, maintains Buy tag | 2 | Investing.com | ||
19.08. | Processa Pharmaceuticals reports preclinical success with NGC-Iri | 1 | Investing.com | ||
16.08. | Processa Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary | 1 | Reuters | ||
13.08. | Processa Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
13.08. | Processa Pharmaceuticals stock hits 52-week low at $1.37 | 1 | Investing.com | ||
07.08. | Processa Pharmaceuticals Inc expected to post a loss of 98 cents a share - Earnings Preview | 1 | Reuters | ||
30.07. | Why Is Processa Pharmaceuticals (PCSA) Stock Up 29% Today? | 2 | InvestorPlace | ||
30.07. | FDA approves Processa Phase 2 study for NGC-Cap, stock rallies 46% | 1 | Seeking Alpha | ||
30.07. | Processa Pharmaceuticals, Inc. - 8-K, Current Report | 5 | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
PFIZER | 26,740 | +0,06 % | Q3-Berichte aus dem S&P 500: Pfizer, Moderna, Micron und 2 Mag-7-Aktien - die vermeintlichen Earnings-Sieger! | © Foto: Foto: Richard Drew/AP/dpaDie "Magnificent 7" bleiben ein entscheidender Motor für das Gewinnwachstum im S&P 500. Analysten erwarten, dass 4 dieser Tech-Giganten - Nvidia, Alphabet, Amazon und... ► Artikel lesen | |
NOVO NORDISK | 107,48 | -0,24 % | Novo Nordisk: Neue Studiendaten zum Wunder-Mittel | Der dänische Konzern Novo Nordisk hat zu Wochenbeginn seine Daten der sogenannten SOUL-Phase-3-Studie zu kardiovaskulären Ereignissen zum oral zu verabreichenden Medikament Rybelsus (Wirkstoff: Semaglutid)... ► Artikel lesen | |
GILEAD SCIENCES | 81,05 | -0,76 % | Gilead And Merck Report Phase 2 Results For Islatravir And Lenacapavir Combination In HIV Treatment | FOSTER CITY (dpa-AFX) - Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the investigational combination of islatravir, an... ► Artikel lesen | |
ELI LILLY | 834,30 | -0,96 % | Neue Medikamente im Rennen: Diese 5 Konzerne attackieren Novo, Lilly auf dem lukrativen Adipositas-Markt | © Foto: DALL-EAuch wenn alle nur noch über KI reden, der Markt für Gewichtsverlust-Mittel explodiert regelrecht. Einige Unternehmen haben gute Chancen, den Marktführern gefährlich zu werden.Es ist still... ► Artikel lesen | |
TEVA | 16,950 | -0,59 % | Alvotech And Teva Pharmaceuticals Announce Expansion Of SELARSDI's Indications | PETAH TIKVA (dpa-AFX) - Alvotech (ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced the FDA has approved SELARSDI in a new presentation... ► Artikel lesen | |
VERTEX PHARMACEUTICALS | 435,10 | -1,11 % | Schlussglocke: Dow im Plus, Travelers, Broadcom, Micron, ASML, Vertex, Nvidia unter den Top-Werten | Die US-Börsen zeigten am heutigen Donnerstag wenig Bewegung. Der Leitindex Dow Jones konnte am Ende mit einem leichten Plus von 0,4 Prozent aus dem Handel gehen, nachdem er im Tagesverlauf bei 43,289... ► Artikel lesen | |
EYEPOINT PHARMACEUTICALS | 9,814 | +0,99 % | EyePoint Pharmaceuticals, Inc.: EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | WATERTOWN, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients... ► Artikel lesen | |
QUANTUM BIOPHARMA | 6,250 | +19,05 % | Quantum Biopharma Ltd.: Quantum Biopharma Posts Link on Its Website to Access the Filed Complaint Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing | To assist enquiries the copy of the complaint can be viewed by clicking the following link: Quantum Bio Pharma Complaint TORONTO, ON / ACCESSWIRE / October 22, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91)... ► Artikel lesen | |
ASTRIA THERAPEUTICS | 10,600 | -2,75 % | Astria Therapeutics' navenibart gains orphan medicinal status from EC | ||
APONTIS PHARMA | 9,640 | 0,00 % | Original-Research: APONTIS PHARMA AG (von Montega AG): Halten (zuvor: Kaufen) | Original-Research: APONTIS PHARMA AG - von Montega AG 18.10.2024 / 13:36 CET/CEST Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group AG. Für den Inhalt der Mitteilung... ► Artikel lesen | |
OPKO HEALTH | 1,322 | +2,23 % | OPKO Health, Inc.: ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program | Brings total awards from BARDA to $110 million for development of broad SARS-CoV-2 and Influenza multispecifics, with potential funding of up to $205 million if all options are executedDevelopment... ► Artikel lesen | |
LIGAND PHARMACEUTICALS | 99,00 | 0,00 % | Kursziel für Ligand Pharma von H.C. Wainwright angehoben | ||
EXSCIENTIA | 4,460 | -4,29 % | Exscientia plc: Exscientia erreicht Meilensteine für zwei Programme im Rahmen der Zusammenarbeit mit Sanofi | Beide Programme demonstrieren die Fähigkeit von Exscientia, hochdifferenzierte, potenziell erstklassige Moleküle zu entwerfen Exscientia erhält für das Erreichen dieser Meilensteine 15 Millionen... ► Artikel lesen | |
JAZZ PHARMACEUTICALS | 103,75 | -1,00 % | RBC lifts Jazz Pharmaceuticals stock target on zanidatamab outlook | ||
ROYALTY PHARMA | 25,380 | 0,00 % | Royalty Pharma plc: Royalty Pharma to Announce Third Quarter 2024 Financial Results on November 6, 2024 |